Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

3S Pharmaceutical Group China

3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.

3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.

We look forward to having opportunity to discuss potential collaboration with you.

Website:
www.3sbio.com
Company Size (Fulltime employees)
5000+
Year of foundation
1993
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Zhao Peng
Senior BD Manager 

Achelios Therapeutics United States

Achelios Therapeutics, Inc., based in RTP Carolina, is a privately held specialty biopharmaceutical company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation by topical application.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Website:
Achelios.com
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
1. License OTC and RX product ex -US , Asia and EU
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
OTC1% diclofenac|Topical NSAID|pain and inflamation|global
Assets Information 2
Prescription 3% Diclofenac|Topical NSAID|Acute and chronic pain, opioid spearing|global
Assets Information 3
5%& 3% Ketoprofen topical|Topical Ketoprofen gel|Migraine, TMJD , Chronic pain|global
Biotech/Pharma Asset Stage
Dr. Crist Frangakis
President & ceo 
Functionality
Management

Adragos Pharma Germany

Private equity firm
Website:
https://www.adragos-pharma.com/
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Both raising further funds and driving deal pipeline
Headquartner in China
No
Biotech/Pharma Category
Mr. Andreas Raabe
Partner 
Functionality
Management

Aeola Health Solutions United States

An investment group transforming

the world of healthcare one sector at a time.

We consolidate CROs and medical labs.
Website:
aeolahealthsolutions.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Find potential investors and strategic partners. Our strategy allows investors to triple their investment.
Headquartner in China
No
Biotech/Pharma Category
Mr. Michael Ezem
Aeola Health Solutions 
Functionality
Investment

Biosion Inc., China

iosion is a global biotechnology company focusing on the discovery and clinical development of innovative biologicals for unmet medical needs. Leveraging our proprietary H³ (High-throughput High-content High-efficiency) antibody platform and SynAb™ technology, Biosion is able to undertake a deep discovery of antibody drug candidates with superior properties, multiple differential choices, and diversified clinical applications. Based on its integrated antibody discovery engine and fueled by our corporate motto of "Innovation for Cures", Biosion is committed to bring next generation innovative drugs to patients around the world.

During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.
Website:
http://en.biosion.com/Home.html
Company Size (Fulltime employees)
51-200
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Seeking partners in big pharma or established biotech companies to co-develop or license assets from Biosion's pipeline or to explore new collaborations for innovative antibody discovery by using our proprietary H³ antibody discovery platform and SynAb™ technology. We are also seeking additional investment to support advancement of our innovative antibody pipeline move into the clinic.
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
BSI-045B|TSLP: High affinity superior humanized antibody for the treatment of asthma and atopic dermatitis (Ex-China global rights)|Severe Asthma|Pending
Assets Information 2
BSI-03802|CD40: Humanized antibody molecule with superior agonist activity (Ex-China global rights)|solid cancer|Pending
Assets Information 3
BSI-001|HER2: hu5G9, best-in-class efficacy partner of trastuzumab and for next generation HER2 ADC development|HER2+ cancer|PCT
Biotech/Pharma Asset Stage
Dr. Mingjiu Chen
CEO 
Functionality
Management

Capital Family Office United States

Investor
Website:
na
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
JV's; Licensing in/out
Headquartner in China
No
Biotech/Pharma Category
Steven Olasky
Pricipal 
Functionality
Investment

Celumigen Pharmaceuticals United States

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.
Website:
celumigen.com
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
Strategic investment/ partnership
Headquartner in China
No
Biotech/Pharma Category
Jake Townsend
CEO 

D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Website:
www.d2mbio.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Nan Bing
CEO 
Functionality
Management

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Website:
www.dao-tun.ch
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
looking for clients and partners who have interest to enter Chinese market for fundraising, licensing, partnering etc.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality
Management

GCV Life India

Life science-focused Innovation licensing organizations looking to commercialize global innovations for the Indian and South Asian markets through a unique partnership-led model.
Website:
http://www.gcvlife.com/
Company Size (Fulltime employees)
11-50
Year of foundation
2008
Partnering Objectives
Please specify your partnering goal
Looking for organizations with deep relationship in the Chinese markets, who can act as our representative in the region to license select products to marketing companies in the Chinese market.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Chirag Jain
Analyst 
Functionality
Business Development